Gilead Sciences, Inc. (NASDAQ:GILD) – Leerink Swann raised their Q4 2017 earnings per share estimates for Gilead Sciences in a report issued on Thursday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will earn $1.94 per share for the quarter, up from their previous forecast of $1.65. Leerink Swann currently has a “Market Perform” rating and a $85.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q1 2018 earnings at $1.79 EPS, Q2 2018 earnings at $1.78 EPS, Q3 2018 earnings at $1.80 EPS, FY2018 earnings at $7.08 EPS, FY2020 earnings at $7.00 EPS and FY2021 earnings at $7.38 EPS.
GILD has been the subject of several other reports. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Oppenheimer assumed coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They issued a “market perform” rating for the company. Mizuho raised their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets lowered their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $85.53.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period last year, the firm earned $2.75 earnings per share.
Large investors have recently bought and sold shares of the business. Keel Point LLC grew its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the period. Paradigm Financial Advisors LLC grew its position in shares of Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC grew its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the period. Arrow Financial Corp grew its position in shares of Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 45 shares during the period. Finally, Auxier Asset Management grew its position in shares of Gilead Sciences by 1.4% during the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after acquiring an additional 96 shares during the period. 75.95% of the stock is owned by institutional investors and hedge funds.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 591,666 shares of company stock valued at $44,466,567. 1.30% of the stock is owned by company insiders.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.57%. Gilead Sciences’s payout ratio is currently 23.66%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.